Carol Agudelo Rico
Research Subjects
Research Interests
Carol Agudelo Rico has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Francisco Javier Meza Cadavid
Integral Solutions SD SAS, Integral Solutions Research, Bogota 110121, Colombia
1 shared publication - Gina Alejandra Díaz Mosquera
Integral Solutions SD SAS, Integral Solutions Research, Bogota 110121, Colombia
1 shared publication - Javier Mauricio Cortes
Integral Solutions SD SAS, Integral Solutions Research, Bogota 110121, Colombia
1 shared publication - Ronald Guillermo Peláez Sánchez
Life and Health Sciences Research Group, Graduate School, CES University, Medellin 050021, Colombia
1 shared publication - Samuel Sarmiento Doncel
Integral Solutions SD SAS, Integral Solutions Research, Bogota 110121, Colombia
1 shared publication
Latest Publications
- Open Access
- 16 February 2023
- Published by MDPI AG in Hematology Reports
- Vol. 15 (1) , 130-150
Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors
The purpose of this narrative review was to provide an overview that allows readers to improve their understanding of hemophilia A, which is considered a genetic disease with a high impact on the quality of life of people who suffer from it is considered one of the diseases with the highest cost for health systems (In Colombia it is part of the five diseases with the greatest economic impact). After this exhaustive review, we can see that the treatment of hemophilia is on the way to precision medicine, which involves genetic variables specific to each race and ethnicity, pharmacokinetics (PK), as well as environmental factors and lifestyle. Knowing the impact of each of these variables and their relationship with the efficacy of treatment (prophylaxis: regular infusion of the missing clotting factor VIII in order to prevent spontaneous bleeding) will allow for individualizing the medical behavior in a cost-effective way. For this is required to build more strong scientific evidence with statistical power that allows us to infer.
- 16 February 2023
- Published by MDPI AG in Hematology Reports
- Vol. 15 (1) , 130-150
Open AccessHaemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors
The purpose of this narrative review was to provide an overview that allows readers to improve their understanding of hemophilia A, which is considered a genetic disease with a high impact on the quality of life of people who suffer from it is considered one of the diseases with the highest cost for health systems (In Colombia it is part of the five diseases with the greatest economic impact). After this exhaustive review, we can see that the treatment of hemophilia is on the way to precision medicine, which involves genetic variables specific to each race and ethnicity, pharmacokinetics (PK), as well as environmental factors and lifestyle. Knowing the impact of each of these variables and their relationship with the efficacy of treatment (prophylaxis: regular infusion of the missing clotting factor VIII in order to prevent spontaneous bleeding) will allow for individualizing the medical behavior in a cost-effective way. For this is required to build more strong scientific evidence with statistical power that allows us to infer.